Hetrombopag Olamine ( DrugBank: Hetrombopag )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 6 |
| 63 | Idiopathic thrombocytopenic purpura | 3 |
60. Aplastic anemia
Clinical trials : 235 / Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05088655 (ClinicalTrials.gov) | June 25, 2021 | 12/10/2021 | A Bioequivalence Study of Hetrombopag in Healthy Subjects | Bioequivalence Study of Different Formulations of Hetrombopag Olamine Tablets in Healthy Subjects | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 45 Years | All | 57 | Phase 1 | China |
| 2 | NCT05088642 (ClinicalTrials.gov) | September 28, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects | A Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 24 | Phase 1 | China |
| 3 | NCT05088174 (ClinicalTrials.gov) | September 3, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy Subjects | A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet;Ciclosporin Soft Capsule | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 26 | Phase 1 | China |
| 4 | NCT04961710 (ClinicalTrials.gov) | September 19, 2019 | 12/7/2021 | Extension Study of Hetrombopag in Severe Aplastic Anemia | Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia | Treatment-naive Severe Aplastic Anemia | Drug: Hetrombopag Olamine;Drug: Placebo | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 15 Years | 75 Years | All | 180 | Phase 3 | China |
| 5 | NCT03825744 (ClinicalTrials.gov) | March 5, 2019 | 30/1/2019 | Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Hetrombopag Olamine+Standard Therapy;Drug: Placebo+Standard Therapy | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 15 Years | 75 Years | All | 180 | Phase 3 | China |
| 6 | NCT03557099 (ClinicalTrials.gov) | June 20, 2018 | 3/6/2018 | A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient | A Multicentre, Open-label, Single-arm, Phase II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 55 | Phase 1/Phase 2 | China |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 363 / Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03222843 (ClinicalTrials.gov) | June 30, 2017 | 18/7/2017 | Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient | A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura | Idiopathic Thrombocytopenic Purpura | Drug: Hetrombopag Olamine;Drug: matching placebo | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 414 | Phase 3 | China |
| 2 | NCT02614846 (ClinicalTrials.gov) | August 2015 | 19/11/2015 | Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients | A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura | Chronic Idiopathic Thrombocytopenic Purpura | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | Both | 29 | Phase 1 | China |
| 3 | NCT02403440 (ClinicalTrials.gov) | April 2014 | 20/3/2015 | A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients | A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | Both | 24 | Phase 1 | China |